PI3K Cancer Research Results

PI3K, Phosphatidylinositide-3-Kinases: Click to Expand ⟱
Source: HalifaxProj(inhibit) CGL-CS
Type:
Phosphatidylinositol 3-kinase (PtdIns3K or PI3K) is a family of enzymes that play a crucial role in cell signaling pathways, particularly in the regulation of cell growth, survival, and metabolism. The PI3K pathway is one of the most frequently altered pathways in human cancer. Inhibition of the PI3K pathway has been explored as a therapeutic strategy for cancer treatment. Several PI3K inhibitors have been developed and are currently being tested in clinical trials. These inhibitors can target specific components of the pathway, such as PI3K, AKT, or mTOR.

Class I phosphoinositide 3-kinase (PI3K)
Class III PtdIns3K
In contrast to the class III PtdIns3K as a positive regulator of autophagy, class I PI3K-AKT signaling has an opposing effect on the initiation of autophagy.

PI3K inhibitors include:
-Idelalisib , Copanlisib, Alpelisib
-LY294002?
-Wortmannin: potent PI3K inhibitor, has some associated toxicity.
-Quercetin:
-Curcumin
-Resveratrol
-Epigallocatechin Gallate (EGCG)
Sepsis, Sepsis: Click to Expand ⟱
Sepsis is a potentially life-threatening condition that arises when the body's response to infection causes injury to its own tissues and organs. This initial stage of sepsis is followed by suppression of the immune system. Common signs and symptoms include fever, increased heart rate, increased breathing rate, and confusion.
Scientific Papers found: Click to Expand⟱
7482- H2,    Molecular Hydrogen Therapy: Mechanisms, Delivery Methods, Preventive, and Therapeutic Application
- Review, Var, NA - Review, IBD, NA - Review, Stroke, NA - Review, Sepsis, NA - Review, AD, NA
Dose↝, *Inflam↓, *IL1β↓, *IL6↓, *TNF-α↓, *neuroP↑, *mTOR↓, *IL10↑, *TGF-β↑, *Sepsis↓, *NRF2↑, *antiOx↑, *Catalase↑, *SOD↑, *GPx↑, *ROS↓, *HO-1↑, *PI3K↑, *Akt↑, *hepatoP↑, *MPO↓, *cardioP↑, CDK4↓, CDK6↑, CD47↓, PI3K↓, Akt↓, Hif1a↓, selectivity↑, *MMP↑, *ATP↑, *ER Stress↓, *CHOP/DDIT3↓, *Casp12↓, *GRP78/BiP↓, *p38↓, *p‑JNK↓, *LC3‑Ⅱ/LC3‑Ⅰ↑, *p‑eIF2α↓, *ATF4↓, *XBP-1↓, *Imm↑, *IFN-γ↓, *IL4↓, *GranB/GZMB↓, NK cell↑, radioP↑, *CD4+↑, CD8+↑, *Dose↝, *other↑, *Dose↝, *antiPs↑, *BioAv↝, *GutMicro↑, Dose↝, *IBI↑, TumCP↓, TumCI↓, TumCMig↓, CD8+↑, PGC-1α↑, Akt↓, SCD1↓, *MDA↓, eff↑, *APP↓, *BACE↓, *Aβ↓, *cognitive↑, *neuroP↑, NP/CIPN↓, *Stroke↓, *NLRP3↓, *ALAT↓, *AST↓, *LPS↓, *hepatoP↑, chemoP↑, *creat↓, *Urea↓, *RenoP↑, *eff↑, Apoptosis↑, XIAP↓, IAP2/BIRC3↓, TumVol↓, MALAT1↓, EZH2↓, miR-124-3p↓, eff↑, ChemoSen↑, *compII↑, *compIII↑, *LDL↓, *Obesity↓, QoL↑, PFS↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

CD47↓, 1,   miR-124-3p↓, 1,   PFS↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

PGC-1α↑, 1,   XIAP↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

SCD1↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 2,   Apoptosis↑, 1,   IAP2/BIRC3↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

EZH2↓, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK4↓, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

PI3K↓, 1,  

Migration(tgid=13) ⓘ

MALAT1↓, 1,   TumCI↓, 1,   TumCMig↓, 1,   TumCP↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

Hif1a↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

NK cell↑, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

CDK6↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ChemoSen↑, 1,   Dose↝, 2,   eff↑, 2,   selectivity↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

EZH2↓, 1,  

Functional Outcomes(tgid=23) ⓘ

chemoP↑, 1,   NP/CIPN↓, 1,   QoL↑, 1,   radioP↑, 1,   TumVol↓, 1,  

Infection & Microbiome(tgid=24) ⓘ

CD8+↑, 2,  
Total Targets: 30

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

compII↑, 1,   Stroke↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   Catalase↑, 1,   GPx↑, 1,   HO-1↑, 1,   MDA↓, 1,   MPO↓, 1,   NRF2↑, 1,   ROS↓, 1,   SOD↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

ATP↑, 1,   compIII↑, 1,   MMP↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ALAT↓, 1,   LDL↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↑, 1,   Casp12↓, 1,   GranB/GZMB↓, 1,   p‑JNK↓, 1,   p38↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↑, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↓, 1,   p‑eIF2α↓, 1,   ER Stress↓, 1,   GRP78/BiP↓, 1,   XBP-1↓, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

LC3‑Ⅱ/LC3‑Ⅰ↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

mTOR↓, 1,   PI3K↑, 1,  

Migration(tgid=13) ⓘ

APP↓, 1,   TGF-β↑, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

ATF4↓, 1,  

Barriers & Transport(tgid=15) ⓘ

IBI↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CD4+↑, 1,   IFN-γ↓, 1,   IL10↑, 1,   IL1β↓, 1,   IL4↓, 1,   IL6↓, 1,   Imm↑, 1,   Inflam↓, 1,   LPS↓, 1,   TNF-α↓, 1,  

Protein Aggregation(tgid=19) ⓘ

Aβ↓, 1,   BACE↓, 1,   NLRP3↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↝, 1,   Dose↝, 2,   eff↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 1,   AST↓, 1,   creat↓, 1,   GutMicro↑, 1,   IL6↓, 1,   Urea↓, 1,  

Functional Outcomes(tgid=23) ⓘ

antiPs↑, 1,   cardioP↑, 1,   cognitive↑, 1,   hepatoP↑, 2,   neuroP↑, 2,   Obesity↓, 1,   RenoP↑, 1,  

Infection & Microbiome(tgid=24) ⓘ

Sepsis↓, 1,  
Total Targets: 64

Scientific Paper Hit Count for: PI3K, Phosphatidylinositide-3-Kinases
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:65  Cells:%  prod#:%  Target#:252  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page